Detection of hepatitis C viral RNA by the polymerase chain reaction by Lucey, Michael R. & Traber, Peter G.
Vol. 13. No. 1. 1991 HEPATOLOGY Elsewhere 193 
HBsAg-transfected mouse thymoma cells) were not 
killed. Hepatocyte killing was increased by treatment 
with y-interferon, which is thought to increase ex- 
pression of MHC antigens on hepatocytes. These obser- 
vations suggest that immune-mediated cell killing may 
contribute greatly to cell injury in hepatitis B infection 
and supports clinical findings that modulation of the 
immune response affects liver injury. 
How well does this remarkable animal model mirror 
the liver injury seen in humans with chronic hepatitis B? 
The answer is not known; however, observations from a 
number of investigators have shown the presence of nu- 
merous CD8+ T lymphocytes in areas of necrosis in 
infected human liver, some of which display signs of ac- 
tivation (6). Furthermore, human hepatocytes in areas 
of periportal necrosis display MHC class I and I1 an- 
tigens (7). Finally, some lymphocytes eluted from hepa- 
titis B-infected human liver tissue recognize HBsAg (8) 
or HBcAg (9). These findings, therefore, demonstrate 
that a t  least the elements of specific hepatitis B- 
directed, cytotoxic T cell-mediated hepatocyte injury in 
humans are in place. These results also provide a ra- 
tionale for the use of interferon or other immunomodu- 
lating agents in the treatment of chronic hepatitis B. 
It will be interesting as well to see future studies from 
this laboratory that will undoubtedly explore the rela- 
tionship between direct cytotoxic effects of hepatitis B 
and immune-mediated injury. These findings also open 
the way for further human studies to determine the 
basis for the varied response of humans to hepatitis B 
infection, ranging from resolved acute hepatitis B to 
chronic hepatitis B in healthy carriers to chronic active 
hepatitis B. 
W. MICHAEL MCDONNELL, M.D. 
REBECCA W. VAN DYKE, M.D. 
Division of Gastroenterology 
University of Michigan 
Ann Arbor, Michigan 481 09 
REFERENCES 
1. Chisari FV, Pinkert CA, Milich DR, Filippi P, McLachlan A, 
Palmiter RD, Brinster RL. A transgenic mouse model of the chronic 
hepatitis B surface antigen carrier state. Science 1985;230: 1157- 
1160. 
2. Chisari FV, Filippi P, McLachlan A, Milich DR, Riggs M, Lee S, 
Palmiter RD, et al. Expression of hepatitis B virus large envelope 
polypeptide inhibits hepatitis B surface antigen secretion in 
transgenic mice. J Virol 1986;60:880-887. 
3. Chisari FV, Filippi P, Buras J, McLachlan A, Popper H, Pinkert CA, 
Palmiter RD, et al. Structural and pathological effects of synthesis 
of hepatitis B virus large envelope polypeptide in transgenic mice. 
Proc Natl Acad Sci USA 1987;84:6909-6913. 
4. Chisari FV, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, 
Sell S, Pinkert CA, et al. Molecular pathogenesis of hepatocellular 
carcinoma in hepatitis B virus transgenic mice. Cell 1989;59:1145- 
1156. 
5. Persing DH, Varmus HE, Ganem D. Inhibition of secretion of 
hepatitis B surface antigen by a related presurface polypeptide. 
Science 1986;234: 1388-1391. 
6. Garcia-Monzou C, Moreno-Otero R, Pajares JM,  Garcia-Sanchez A, 
Lopez-Botet M, deLandazuri MO, Sanchez-Madrid F. Expression of 
a novel activation antigen on intrahepatic CD8 + T lymphocytes in 
viral chronic active hepatitis. Gastroenterology 1990;98: 1029- 1035. 
7. van den Oord JJ ,  de Vos R, Desmet VJ. In situ distribution of MHC 
products and viral antigens in chronic hepatitis B virus infection: 
evidence that HBc-containing hepatocytes may express HLA-DR 
antigens. HEPATOLOGY 1986;6:981-989. 
8. Barnaba V, Franco A, Alberti A, Balsano C, Benvenuto R, Balsano 
F. Recognition of hepatitis B virus envelope proteins by liver 
infiltrating T lymphocytes in chronic HBV infection. J Immunol 
9. Ferrari C, Mondelli MU, Penna A, Fiaccadori F, Chisari FV. 
Functional characterization of cloned intrahepatic HBV nucleo- 
protein specific helper T cell lines. J Immunol 1987;139:539-544. 
1989;143:2650-2655. 
DETECTION OF HEPATITIS C VIRAL RNA BY 
THE POLYMERASE CHAIN REACTION 
Weiner AJ, Kuo G, Bradley OW, Bonino F, Saracco G, 
Lee C, Rosenblatt J ,  et al. Detection of hepatitis C viral 
sequences in non-A, non-B hepatitis. Lancet 1990;335: 
Garson JA, Tedder RS, Briggs M, Tuke P, Glazebrook 
JA, Trute A, Parker D, et al. Detection of hepatitis C 
viral sequences in blood donations by “nested poly- 




These studies used the polymerase chain reaction 
(PCR) to identify hepatitis C virus (HCV) RNA in 
clinical samples collected from patients with chronic 
liver disease or from blood donors. The relative role of 
this assay compared with detection of HCV antibodies 
in serum was evaluated. Weiner and colleagues found 
that 9 of 15 patients with non-A, non-B (NANB) chronic 
hepatitis and the only patient with cryptogenic cir- 
rhosis had persistent antibodies to a nonstructural 
protein of HCV (C100-3). Seven of the 10 antibody- 
positive patients had HCV RNA detected by a highly 
sensitive PCR assay; two of the antibody-negative 
patients also had HCV RNA. The pattern of viral RNA 
and antibody was evaluated in one patient with acute 
posttransfusion NANB hepatitis (PTNANB) and in 
three chimpanzees with acute infection. Viral RNA was 
detected early after infection and, in each case, before 
the appearance of antibody. In one chimpanzee, viral 
RNA disappeared when antibody became detectable. 
The authors conclude that most patients with chronic 
NANB liver disease have HCV infection. 
Garson and colleagues found that 6 of 1,100 donor 
blood units were repeatedly positive for antibodies to 
the C100-3 antigen (anti-Cl00-3). Only one of these six 
donor units was found to contain HCV RNA by a 
“nested PCR’ assay. Nested PCR refers to the use of 
two successive rounds of amplification, with the second 
round using primers internal to, or nested within, the 
original two primers. The positive donor unit was the 
only one of the six antibody-positive units to cause 
posttransfusion hepatitis in a recipient. Sera from 
three other confirmed cases of posttransfusion hepa- 
titis were evaluated and in each case one donor unit of 
blood was found to contain HCV RNA and anti-C100-3. 
The authors concluded that anti-C100-3 may not be a 
good predictor of infectivity in blood donors and that 
direct identification of viral RNA may be required. 
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COMMENTS 
These studies underscore the usefulness of a powerful 
research tool, the PCR, to address clinically important 
questions concerning the biology of hepatitis viruses. 
With this method one can definitively identify viral 
nucleic acid in clinical samples and, therefore, better 
define the clinical course of infection and the meaning of 
HCV antibodies. Our comments will address PCR 
methodology and the clinical usefulness of these au- 
thors’ observations. 
Interpretation of PCR data in clinical studies requires 
consideration of methodological issues. PCR entails the 
use of oligonucleotide primers, which are homologous to 
known nucleic acid sequences to enzymatically amplify 
the DNA between the two primers. The method is 
sensitive enough to amplify a single DNA molecule to 
levels that are easily detected. As used in these studies, 
the method can be modified to amplify RNA sequences 
by first synthesizing complementary DNA (cDNA) with 
the enzyme reverse transcriptase. 
Use of PCR can generate false-positive and false- 
negative results. Much attention has been devoted to the 
concern over false-positive results when using PCR 
assays. Contaminated assay solutions or “carryover” 
from pipettes can result in identification of a DNA 
fragment in true negative samples. As used in these two 
studies, strict adherence to published laboratory precau- 
tions (2) and the inclusion of negative controls for each 
assay reduce the likelihood of false-positive results. 
Because of the exquisite sensitivity of PCR, the 
possibility of false-negative results is often overlooked. 
False-negative results may be more likely when RNA is 
amplified because of the need for cDNA synthesis before 
PCR. Therefore, when the sensitivity of PCR assays is 
evaluated, the reverse transcription reaction must be 
included in the assessment. Weiner et al. were able to 
detect 3 CID (chimpanzee infectious doses)/ml with their 
assay. These investigators synthesized cDNA from 
chimpanzee serum and amplified the cDNA with oligo- 
nucleotide primers; the PCR products were probed with 
a radiolabeled oligonucleotide, which greatly increases 
the sensitivity for detection of amplified DNA. In 
contrast, Garson used a partial clone of HCV (ds DNA) 
to assess sensitivity and, therefore, did not include the 
cDNA-synthesis step. Despite this caveat, Garson’s use 
of a second round of amplification using nested primers 
achieved a level of sensitivity similar to that of the study 
by Weiner without using a radioactive probe; this 
represents a significant simplification of the method and 
makes it potentially more amenable for use in clinical 
laboratories. 
An additional variable is the amount of serum or 
tissue used to extract nucleic acids for use in the assay. 
In the study by Garson, as little as 5 p1 serum was used 
to extract nucleic acids, and only 20% of this was used in 
the reverse transcriptase reaction. If the average 
number of virions in infected serum is lo2 to 104/ml as 
suggested by Weiner, there may be < 1  virion/5 p1 
plasma. 
Perhaps the most important consideration for false- 
negative results is the existence of different strains or 
subtypes of HCV. In Japan, a t  least two strains of HCV 
have been identified (3). These two strains, termed 
HCV-K1 and HCV-K2, have 80%, and 67% homoloa, 
respectively, with the sequence of the original isolate 
over the limited area of reported sequence (4). Sig- 
nificant mismatches between PCR primers and viral 
sequence could markedly diminish the sensitivity of 
the assay or completely eliminate amplification. Fur- 
thermore, significant nucleotide or amino acid sequence 
differences in one portion of the virus may not affect 
antibody recognition of (3100-3 protein (2). Therefore, 
HCV strains in various populations must be sequenced 
and primers carefully chosen to amplify prevalent 
strains in the population under study. This is a potential 
reason for the low detection rate of HCV RNA in the 
study by Garson, although the lack of infectivity of 
anti-HCV-positive, HCV RNA-negative blood argues 
against this possibility. 
These studies assist the practicing physician in inter- 
preting anti-HCV serological results (using anti-C100-3 
tests) in two important clinical situations. The first 
concerns patients with acute or chronic PTNANB 
hepatitis; the second concerns persons found to have 
anti-C100-3 without evidence of liver injury. In both 
circumstances the crucial question is whether the 
person has HCV RNA. Weiner’s study indicates that 
the presence of anti-C100-3 in persons with chronic 
PTNANB hepatitis is frequently accompanied by HCV 
RNA, indicating that the patient is infectious. Fur- 
thermore, these data hint that viral replication is a 
necessary factor to sustain hepatic injury in chronic 
PTNANB hepatitis. Similarly, the data from one chim- 
panzee and one surgical patient, which show that acute 
HCV hepatitis is accompanied by high levels of HCV 
RNA, suggests that viral replication is involved in the 
mechanism for hepatic injury in acute PTNANB hepa- 
titis also. 
A crucial observation of these authors is that HCV 
RNA may be present in acute or chronic episodes of 
PTNANB hepatitis when anti-Cl00-3 is not detectable. 
This may not represent a false-negative result so much 
as the temporal pattern for development of this par- 
ticular antibody. Moreover, previous studies by Alter 
et al. (5) would suggest that some (2 of 5) patients with 
acute PTNANB hepatitis do not proceed to anti-C100-3 
positivity. In that study, HCV RNA was not measured, 
so the conclusion that these anti-C 100-3-negative acute 
PTNANB hepatitides were indeed HCV-induced re- 
mains presumptive. Nonetheless, taken together one 
can conclude that the absence of anti-C100-3 in a 
clinical setting suggestive of HCV infection must not be 
taken to indicate that HCV has been excluded from the 
differential diagnosis. Put more simply, HCV infection 
may be present when currently available anti-HCV tests 
are negative. 
What is the significance of positive results for anti- 
C100-3 in the absence of overt liver dysfunction? Garson 
et al. address this important question. We assume 
(although it is not stated) that all blood for transfusion 
in their study was screened for elevation of serum 
transaminases and HBc antibody. Their data show that 
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these blood donors frequently do not harbor HCV RNA 
and are not infectious. This is borne out by the absence 
of PTNANB hepatitis in the five recipients of anti- 
C100-3 HCV RNA-negative blood, whereas the only 
recipient of anti-C100-3-positive, HCV RNA-positive 
blood did contract PTNANB hepatitis. It would be of 
interest to know the subsequent clinical course of the 
donor of the latter blood. At present it is unclear whether 
HCV infection can occur without hepatitis, either 
acutely or chronically. If chronically infected, this donor 
could be analogous to a benign chronic carrier of HBsAg. 
Conversely, in view of Weiner’s data, one may question 
why this donor did not have hepatitis if viral replication 
and hepatitis appear to go hand in hand. Clearly there is 
much to be learned about the mechanisms of cellular 
injury in HCV infection. 
Garson’s study does not indicate whether there were 
any anti-HCV-negative cases of PTNANB hepatitis 
among the recipients of the 1,100 units of blood tested. 
In a previous study by Van der Poel et al. (61, of 5,150 
units of blood transfused into 383 recipients, 6 of 34 
(18%) recipients of anti-C100-3-positive blood con- 
tracted NANB hepatitis. This result is similar to that of 
Garson - one of six recipients of anti-C100-3-positive 
blood. Interestingly, in Van der Poel’s study, 3 of 349 
recipients of anti-C100-3-negative blood contracted 
NANB hepatitis. In contrast, Esteban et al. (7 )  have 
reported on 280 transfusion recipients of 1,109 units of 
blood among whom 27 (9.6%) contracted PTNANB 
hepatitis. In this study anti-HCV status was assessed by 
anti-C-100 ELISA and also by the more recently 
developed recombinant immunoblot assay, which recog- 
nizes antibodies to two HCV epitopes, C-100 and 5.1.1. 
HCV RNA was not measured. Sixteen of the 27 
PTNANB patients in Esteban’s study received anti- 
HCV-positive blood, whereas 11 received anti-HCV- 
negative blood. However, 24 of 27 patients with 
PTNANB hepatitis became anti-HCV-positive during 
52 wk of follow-up. Only two recipients of anti-HCV- 
positive blood did not contract PTNANB hepatitis. It 
is not clear why there was so marked a disparity in 
infectious potential of anti-HCV-positive blood between 
the studies by Garson and Van Der Poel and that of 
Esteban (18% vs. 88%). However, in agreement with 
Weiner’s data, one can infer from Esteban’s study that 
infectious HCV may be present in blood without de- 
tectable anti-HCV. The application of PCR technology to 
identification of HCV RNA in potentially infected sera 
is one possible solution to this clinical conundrum. 
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NEW INSIGHTS INTO CANALICULAR ORGANIC 
ANION SECRETION 
Oude Elferink RPJ, Ottenhoff R, Liefting WGM, Schoe- 
maker B, Groen AK,  Jansen PLM. ATP-dependent efflux 
of GSSG and GS-conjugate from isolated rat hepato- 
cytes. Am J Physiol 1990;258:G699-G706. 
EDITOR’S ABSTRACT 
The effect of partial and complete dissipation of the 
membrane potential and partial depletion of cellular 
ATP content on the efflux of dinitrophenyl-glutathione 
and oxidized glutathione was examined in hepatocytes 
isolated from normal and mutant (TR- ) rats exhibiting 
defective organic anion transport. Whereas alterations 
in the membrane potential difference had no effect on 
the initial efflux rate of dinitrophenyl-glutathione and 
oxidized glutathione, depletion of cellular ATP in- 
hibited dinitrophenyl-glutathione and oxidized glu- 
tathione efflux and a linear relationship between the 
cellular ATP content and the initial efflux rate of 
dinitrophenyl-glutathione was observed in normal iso- 
lated rat hepatocytes. In contrast, depletion of cellular 
ATP content had no significant effect on the slower rate 
of dinitrophenyl-glutathione efflux from TR- rat he- 
patocytes. These findings implicate an ATP-dependent 
hepatic transport system for oxidized glutathione and 
glutathione conjugates that is absent in TR- mutants. 
Kitamura T,  Jansen P, Hardenbrook, Kamimoto Y, 
Gatmaitan 2, Arias IM. Defective ATP-dependent bile 
canalicular transport of organic anions in mutant (TR 1 
rats with conjugated hyperbilirubinemia. Proc Natl 
Acad Sci USA 1990;87:3557-3561. 
EDITOR’S ABSTRACT 
Fluorescence image analysis reveals normal se- 
cretion of a fluorescent bile acid (fluorescein isothiocy- 
anate glycocholate into the canalicular lumen of iso- 
lated normal and TR- mutant rat hepatocyte couplets, 
but negligible canalicular accumulation of a non-bile- 
acid organic anion (carboxydichlorofluorescein diac- 
etate) in TR- hepatocyte couplets. Canalicular mem- 
